



Pymaceuticals, Inc. Capomulin Comparison for Effects on Squamous Cell Carcinoma (SCC)


Pymaceuticals, Inc. recently conducted a study on a variety of treatment regimes for squamous cell carcinoma (SCC). The study was conducted in order to compare Pymaceutical's drug, Capomulin, to other mainstream drugs for this disease. Over 45 days, 249 mice with SCC were administered the variety of treatment regimes, including Capomulin, and studied to observe the results of the treatment and monitor tumor size. Using the collected data, we can surmise that Capomulin was the most effective drug at reducing the average tumor size.

The data provided was cleaned by removing duplicates and sorting the data to determine skew. Overall, the data provided was thorough. Drugs were administered to similar group sizes and administered evenly to male and female mice.





While most drugs appeared to cause tumor volumes to increase over time, Ramicane and Capomulin reduced or contained overall tumor volume.



Although the data does show that Ramipril had similar effects in reducing tumor volume, Capomulin was the most effective drug for reducing the average tumor size. The collected data demonstrates a linear correlation between tumor weight and tumor volume.

